Senex Biotechnology was founded by Dr. Igor Roninson, based on the discovery in his academic laboratory of a novel biological pathway associated with aging (senescence) and involved in cancer and other chronic diseases as well as the use of functional genomics technologies to identify novel drug targets that are required by tumor cells but not by normal tissues. Senex has started its operations in Albany, NY in 2004 and relocated to Columbia, SC in 2011. Senex has won 14 competitive grant awards from the National Institutes of Health, Department of Defense Congressionally Directed Medical Research Programs and Alzheimer’s Drug Discovery Foundation. Senex’s work on prostate cancer drug development is currently supported by a Phase II Small Business Innovation Research (SBIR) grant from the National Cancer Institute.
senexbio.com 